Dr Yemi Onakunle, Co-Founder/CEO, Mabswitch (middle) receives the MBC BioLabs Diversity Golden Ticket supported by AbbVie from Dr Douglas Crawford, Managing Partner, Mission Capital (right) and Ms Flavia Nachbar, Public and Alliance Relations Manager, MBC BioLabs (left)

The MBC BioLabs Diversity Golden Ticket supported by AbbVie award provides lab space fitted with state-of-the-art research equipment, professional support staff, conference room space for meetings, and a vibrant, collaborative community to share ideas and expertise with other exciting life science companies. The Golden Ticket is awarded to early-stage companies developing novel, transformational therapies.

“We are very pleased and excited to be a winner of the prestigious MBC BioLabs Diversity Golden Ticket sponsored by Abbvie Inc – one of the leading biopharmaceutical companies in the world.  This Golden Ticket which provides access to highly coveted laboratory space and state-of-the-art equipment will facilitate the important research that we will undertake to develop and create first and/or best-in-class regulatable next-generation antibody based immunotherapies to cure cancers and other devastating chronic diseases. We are very grateful to MBC BioLabs and Abbvie for their recognition of our team, the proprietary nature of our technologies and the potential to develop innovative drugs that will improve the lives of patients globally.”

Dr. Yemi Onakunle, CEO, Mabswitch

About MBC BioLabs

LinkedIn

Categories: News